Our Story

Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.

After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device industry’s first successful large-scale Level l, randomized sham-controlled trial for chronic vertebrogenic low back pain. Relievant then sponsored the INTRACEPT Study — a Level l, prospective, randomized clinical study comparing the Intracept Procedure to conservative care for patients with chronic vertebrogenic low back pain.

The INTRACEPT Study was initiated in 2017, and enrollment was stopped for superiority of the primary and all secondary endpoints in January 2019.  With significant treatment effects demonstrated, results were published in June of that year.

In 2019, 24 month results from the SMART trial were published – followed in 2020 by a publication showing previously published outcomes were durable through 5 years.

  • 2006

    October: Relievant Founded

  • 2008

    September: CE Mark Approval

  • 2010

    June: Pilot Study Completed

  • 2015

    February: SMART Trial Completed

  • 2016

    July: FDA 510(k) Clearance

  • 2018

    February: SMART Trial Publication – 12 Month Results

    July: First Commercial Intracept Procedures

  • 2019

    January: INTRACEPT Trial enrollment stopped early for superiority

    April: SMART Trial Publication – 24 Month Results

    June: INTRACEPT Trial publication – 3 month Interim Analysis results

  • 2020

    May: Long-term, 5 year SMART Trial Publication